Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Vi-CRM197 glycoconjugate vaccine vs Vi polysaccharide vaccine in adults
2010-021874-12Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Vi-CRM197 in typhoid fever (4 arms), sponsored by Novartis. Primary endpoints: Immunogenicity Endpoints and Safety endpoints. Started Aug 2010; status: completed.
02
Drugs
Vi-CRM197
03
Conditions
typhoid fever
Beyond the preview
Go deeper on 2010-021874-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021874-12.